Home › Chronic Lymphocytic Leukemia › New Jersey
Chronic Lymphocytic Leukemia clinical trials in New Jersey
13 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in New Jersey.
Cities in New Jersey
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Jersey City Medical Center, Jersey City
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Sidney Kimmel Comprehensive Cancer Center Washington Twp, Sewell
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Titan Health Partners Llc Dba Astera Cancer Care, East Brunswick
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016), Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Hackensack Meridian Health, Hackensack
- Carol G Simon Cancer Center, Morristown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Hackensack
- Research Site, New Brunswick
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Atlantic Health, Morristown
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Jefferson Cherry Hill Hospital, Cherry Hill
- Sidney Kimmel Cancer Center Washington Township, Sewell
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Sep 2, 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Englewood Hospital and Medical Center, Englewood
- CentraState Medical Center, Freehold
- Hackettstown Medical Center, Hackettstown
- and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Summit Medical Group, Florham Park
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT07271667Study of SGR-1505 in Mature B-Cell Neoplasms
- Regional Cancer Care Associates, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Regional Cancer Care Associates /ID# 244620, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04895436From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.